Embedded Files
Our research primarily focuses on elucidating the impact of food-associated microbes on host metabolism and intestinal microbiota in the context of health and disease, with particular attention to obesity, metabolic disorders, and inflammation. A key aspect of our work is investigating the functional mechanisms of lactic acid bacteria in fermented foods and their potential health benefits. To further explore the efficacy of probiotics and other bioactive microbes, our research employs C. elegans as a model organism, providing a fundamental understanding of microbe-host interactions. Our expertise encompasses the cultivation of aerobic and anaerobic bacteria, DNA-based genotyping, immunological assays, next-generation sequencing, and animal models, integrating multidisciplinary approaches to advance knowledge in microbiome research and its applications in health sciences.
Our research primarily focuses on elucidating the impact of food-associated microbes on host metabolism and intestinal microbiota in the context of health and disease, with particular attention to obesity, metabolic disorders, and inflammation. A key aspect of our work is investigating the functional mechanisms of lactic acid bacteria in fermented foods and their potential health benefits. To further explore the efficacy of probiotics and other bioactive microbes, our research employs C. elegans as a model organism, providing a fundamental understanding of microbe-host interactions. Our expertise encompasses the cultivation of aerobic and anaerobic bacteria, DNA-based genotyping, immunological assays, next-generation sequencing, and animal models, integrating multidisciplinary approaches to advance knowledge in microbiome research and its applications in health sciences.
PREVIOUS RESEARCHES
PREVIOUS RESEARCHES
Lactobacillus rhamnosus LRH05 (LRH05) and Lactobacillus reuteri LR47 (LR47) are screened out with lower triglyceride expression in vitro. The mice are fed a control diet (CD), HFD, or HFD supplemented with a dose of LRH05 or LR47 at 10^9 CFU per mouse per day for 10 weeks, respectively. The results demonstrate that LRH05, but not LR47, significantly reduce body weight gain and the weight of WAT, as well as improve hepatic steatosis and glucose intolerance. LRH05 regulates the Mogat1, Igf-1, Mcp-1, and F4/80 mRNA expression and decreases macrophage infiltration in WAT. LRH05 shows an increase in butyric and propionic acid-producing bacteria, including Lachnoclostridium, Romboutsia, and Fusobacterium that is coincident with the increased fecal propionic acid and butyric acid levels. LRH05 shows a strain-specific effect on ameliorating the pro-inflammatory process by reducing inflammatory macrophage infiltration and the expression of inflammation-related genes in mice. Thus, LRH05 can be considered a potential probiotic strain to prevent obesity.
Lactobacillus rhamnosus LRH05 (LRH05) and Lactobacillus reuteri LR47 (LR47) are screened out with lower triglyceride expression in vitro. The mice are fed a control diet (CD), HFD, or HFD supplemented with a dose of LRH05 or LR47 at 10^9 CFU per mouse per day for 10 weeks, respectively. The results demonstrate that LRH05, but not LR47, significantly reduce body weight gain and the weight of WAT, as well as improve hepatic steatosis and glucose intolerance. LRH05 regulates the Mogat1, Igf-1, Mcp-1, and F4/80 mRNA expression and decreases macrophage infiltration in WAT. LRH05 shows an increase in butyric and propionic acid-producing bacteria, including Lachnoclostridium, Romboutsia, and Fusobacterium that is coincident with the increased fecal propionic acid and butyric acid levels. LRH05 shows a strain-specific effect on ameliorating the pro-inflammatory process by reducing inflammatory macrophage infiltration and the expression of inflammation-related genes in mice. Thus, LRH05 can be considered a potential probiotic strain to prevent obesity.
Ref: Mol. Nutr. Food Res.,2021
DOI : 10.1002/mnfr.202100348
We demonstrated that the specific bacterial strains isolated from kefir, Lactobacillus kefirnofaciens M1 and Lactobacillus mali APS1, possess obesity and anti-obesity effects, respectively, in high-fat diet. We systematically investigated whether APS1 and M1 affect energy homeostasis and lipid metabolism in HFD-induced obese mice and how this might be achieved. We observed that the M1/APS1 intervention influenced fat accumulation by regulating adipogenesis and inflammation-related marker expression both in vitro and in a HFD-induced obesity mice model. We also observed putative links between key taxa and possible metabolic processes of the gut microbiota. Notably, families Christensenellaceae and S24_7 were negatively correlated with body weight gain through increase in the essential esterized carnitine for energy expenditure. These results suggest the importance of specific probiotic interventions affecting leanness and obesity of subjects under a HFD, which are operated by modulating the tripartite relationship among the host, microbiota, and metabolites.
We demonstrated that the specific bacterial strains isolated from kefir, Lactobacillus kefirnofaciens M1 and Lactobacillus mali APS1, possess obesity and anti-obesity effects, respectively, in high-fat diet. We systematically investigated whether APS1 and M1 affect energy homeostasis and lipid metabolism in HFD-induced obese mice and how this might be achieved. We observed that the M1/APS1 intervention influenced fat accumulation by regulating adipogenesis and inflammation-related marker expression both in vitro and in a HFD-induced obesity mice model. We also observed putative links between key taxa and possible metabolic processes of the gut microbiota. Notably, families Christensenellaceae and S24_7 were negatively correlated with body weight gain through increase in the essential esterized carnitine for energy expenditure. These results suggest the importance of specific probiotic interventions affecting leanness and obesity of subjects under a HFD, which are operated by modulating the tripartite relationship among the host, microbiota, and metabolites.
Ref: Front. Microbiol., 2020 https://doi.org/10.3389/fmicb.2020.01454
鼠李糖乳桿菌LRH05分離株及其用途
LACTOBACILLUS RHAMNOSUS LRH05 ISOLATE AND USES OF THE SAME
Patent Number: I776375
Issued Date: 2022/09/01
Inventor:
陳詠宗 (中華民國); CHEN, YUNG TSUNG (TW);
林金生 (中華民國); LIN, JIN-SENG (TW)
Page updated
Google Sites
Report abuse